Article

Gout in women: Differences in risk factors in young and older women

Department of Rheumatology, Counties Manukau District Health Board, Private Bag 93311, Otahuhu, Auckland 1640, New Zealand. .
The New Zealand medical journal 11/2012; 125(1363):39-45.
Source: PubMed

ABSTRACT

To describe the clinical characteristics of female patients with gout, assess risk factors in this group and to identify any differences between pre- and postmenopausal women with this diagnosis.
We retrospectively reviewed the case records of all women who were seen with gout in a secondary care setting (inpatient and outpatient) at Counties Manukau District Health Board between July 2007 and July 2008. Demographic data, risk factors for gout and information on urate-lowering therapy was collected. A cut-off of less than and equal to 50 years was used to estimate pre-menopausal status.
122/509 (24%) of patients seen with gout were female. Fourteen female patients were less than or equal to 50 years of age; all of these patients were either Maori (43%) or of Pacific Island ethnicity (57%). Comorbidities in those =50 years old were renal impairment (78.6%), hypertension (64.3%), congestive heart failure (43%) and diabetes mellitus (42.9%). Comorbidities in women >50 years old were similar: hypertension (77%), renal impairment (70%), dyslipidemia (53%) and diabetes mellitus (50%). Ischemic heart disease was more common in older women (43% vs 7%), P<0.01. Mean body mass index (BMI) was significantly higher in the younger women (43.5 vs 33.1), P<0.01. Half of all the female patients were on diuretics, and medication used to lower uric acid level was prescribed in 35.7% of women less than and equal to 50 years of age, and 42.59% of women >50 years of age.
Women who develop gout are more likely to be over the age of 50, have other comorbidities and be on diuretics. In comparison, younger women who develop gout have similar risk factors but tended to have a higher body mass index and are more likely to be of Maori or Pacific Island ethnicity.

Download full-text

Full-text

Available from: Sunil Kumar, Sep 15, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: About 2500 years ago, gout was observed by Hippocrates and many people suffered severe pain and deformity. Lifestyle and diet play a significant role in gout and serum uric acid levels. Epidemiological and research studies have supported this evidence. Many recommendations and guidelines from different parts of the world mention the impact of diet on gout. Recently, new research has shown associations between vitamin C, alcohol, coffee, tea, milk and yogurt with uric acid and the risk of gout. Our review summarizes recently published research regarding dietary impact on the risk of gout and serum uric acid levels. © 2015 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd.
    Preview · Article · Jun 2015 · International Journal of Rheumatic Diseases
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: The objective of this study was to assess the real-world comparative effectiveness of continuing on allopurinol versus switching to febuxostat. Methods: In a retrospective claims data study of enrollees in health plans affiliated with Optum, we evaluated patients from February 1, 2009, to May 31, 2012, with a gout diagnosis, a pharmacy claim for allopurinol or febuxostat, and at least 1 serum uric acid (SUA) result available during the follow-up period. Univariate and multivariable-adjusted analyses (controlling for patient demographics and clinical factors) assessed the likelihood of SUA lowering and achievement of target SUA of less than 6.0 mg/dL or less than 5.0 mg/dL in allopurinol continuers versus febuxostat switchers. Results: The final study population included 748 subjects who switched to febuxostat from allopurinol and 4795 continuing users of allopurinol. The most common doses of allopurinol were 300 mg/d or less in 95% of allopurinol continuers and 93% of febuxostat switchers (prior to switching); the most common dose of febuxostat was 40 mg/d, in 77% of febuxostat switchers (after switching). Compared with allopurinol continuers, febuxostat switchers had greater (1) mean preindex SUA, 8.0 mg/dL versus 6.6 mg/dL (P < 0.001); (2) likelihood of postindex SUA of less than 6.0 mg/dL, 62.2% versus 58.7% (P = 0.072); (3) likelihood of postindex SUA of less than 5.0 mg/dL, 38.9% versus 29.6% (P < 0.001); and (4) decrease in SUA, 1.8 (SD, 2.2) mg/dL versus 0.4 (SD, 1.7) mg/dL (P < 0.001). In multivariable-adjusted analyses, compared with allopurinol continuers, febuxostat switchers had significantly higher likelihood of achieving SUA of less than 6.0 mg/dL (40% higher) and SUA of less than 5.0 mg/dL (83% higher). Conclusions: In this "real-world" setting, many patients with gout not surprisingly were not treated with maximum permitted doses of allopurinol. Patients switched to febuxostat were more likely to achieve target SUA levels than those who continued on generally stable doses of allopurinol.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.
    Full-text · Article · Nov 2015 · Journal of clinical rheumatology: practical reports on rheumatic & musculoskeletal diseases